FTCD

FTCD is a liver-enriched bifunctional enzyme (formiminotransferase cyclodeaminase) that links histidine catabolism to one-carbon/folate metabolism and most likely arose by fusion of two ancestral bacterial enzymatic domains (PMID:10773664). Beyond this metabolic activity, FTCD is a Golgi-localized membrane tethering factor: it binds the polyglutamate motifs of p47 or p97 to assemble a large FTCD-p97/p47-FTCD complex that drives p97/p47-mediated Golgi membrane fusion and reassembly during mitosis, and an engineered mitochondria-targeted FTCD recruits endogenous p97 and p47 to aggregate mitochondria, establishing FTCD's intrinsic tethering function (PMID:33555040). In the liver, FTCD acts as a tumor suppressor: hepatocyte-specific loss promotes both carcinogen-induced and spontaneous hepatocarcinogenesis by activating the PTEN/Akt/mTOR axis to upregulate PPARγ and SREBP2, driving lipid accumulation (PMID:37675273), whereas restoring FTCD in HCC cells depletes tetrahydrofolate, lowers NADPH and GSH ratios, and triggers ROS-driven mitochondrial oxidative stress, cytochrome c release, and caspase-dependent apoptosis (PMID:34774692). A human FTCD missense variant (p.Val101Met) reduces arsenic methylation efficiency, consistent with FTCD supplying folate-cycle one-carbon units for methylation reactions (PMID:30893314).

1. 2000 Medium

   Established the molecular identity of FTCD as a bifunctional histidine-catabolic enzyme connecting to folate metabolism, framing it as a metabolic gene of likely fusion origin.

   Evidence cDNA cloning, sequence/domain homology to two bacterial ORFs, and liver-enriched tissue expression analysis

   PMID:10773664

   Open questions at the time

   • No in vitro enzymatic reconstitution or mutagenesis of the catalytic domains
   • Fusion origin inferred from homology, not experimentally validated
   • No structural model of the bifunctional protein
2. 2019 Medium

   Linked FTCD genotype to one-carbon metabolic output in humans, showing its histidine-derived folate cycle activity supplies methyl groups relevant to arsenic methylation.

   Evidence Exome-wide association in 1,660 Bangladeshi individuals with urinary arsenic metabolite phenotypes and Kozak/start-codon analysis

   PMID:30893314

   Open questions at the time

   • No direct enzymatic assay of the variant protein
   • Causality of the coding change versus linked regulatory effects not resolved
   • Mechanism connecting FTCD activity to methylarsenical output not biochemically dissected
3. 2021 High

   Revealed a moonlighting structural role distinct from metabolism — FTCD is a membrane tethering factor for Golgi reassembly — answering how Golgi membranes are bridged during p97/p47-mediated fusion.

   Evidence Co-IP, reciprocal in vitro binding via polyglutamate motifs, in vitro and in vivo Golgi reassembly assays, and mitochondria-retargeting tethering assay

   PMID:33555040

   Open questions at the time

   • Structural basis of the FTCD-p97/p47-FTCD complex not solved
   • Relationship between catalytic and tethering functions unclear
   • Whether tethering is regulated through the cell cycle not defined
4. 2021 Medium

   Connected restoration of FTCD to tumor suppression mechanistically, showing it perturbs folate/redox metabolism to drive mitochondrial apoptosis in HCC.

   Evidence Nanoparticle-delivered FTCD overexpression in HCC cells with THF, NADPH/NADP+, GSH/GSSG, ROS, cytochrome c, caspase, and in vivo tumor readouts

   PMID:34774692

   Open questions at the time

   • Single lab without direct enzymatic reconstitution
   • Whether the apoptotic effect requires FTCD catalytic activity not tested
   • Off-target effects of nanoparticle delivery not excluded
5. 2023 High

   Demonstrated FTCD is a hepatic tumor suppressor in vivo and defined the signalling cascade through which its loss promotes lipid accumulation and cancer.

   Evidence Hepatocyte-specific Ftcd knockout mice, DEN-induced HCC, multi-omics, and Akt inhibitor rescue

   PMID:37675273

   Open questions at the time

   • How metabolic FTCD loss mechanistically engages PTEN/Akt/mTOR not fully resolved
   • Contribution of the Golgi tethering function to tumor suppression untested
   • Direct molecular target linking FTCD to PTEN regulation unknown
6. 2024 Low

   Associated FTCD expression with therapy response, noting its downregulation in lenvatinib-resistant HCC and restoration by cabozantinib.

   Evidence Lenvatinib-resistant cell lines, xenograft proteomics, western blot, and immunohistochemistry

   PMID:38815631

   Open questions at the time

   • Descriptive association only — no mechanism by which cabozantinib restores FTCD
   • Causal role of FTCD in resistance not established
   • Not independently confirmed

• How FTCD's metabolic enzymatic function, its Golgi membrane-tethering role, and its tumor-suppressor signalling are mechanistically integrated remains unresolved.
• No structure of the catalytic or tethering complex
• Whether catalytic activity is required for tumor suppression or tethering untested
• Direct molecular link between FTCD loss and PTEN/Akt/mTOR activation unknown